Comparative Pharmacology
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus PERIACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIPHENHYDRAMINE HYDROCHLORIDE versus PERIACTIN.
DIPHENHYDRAMINE HYDROCHLORIDE vs PERIACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H1 receptors, reducing allergic symptoms; also exerts anticholinergic, sedative, and antiemetic effects via central and peripheral receptor blockade.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
25-50 mg orally or intramuscularly every 4-6 hours as needed; maximum 300 mg per day.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
None Documented
None Documented
Terminal elimination half-life 4–10 hours (mean ~7 hours); prolonged in elderly, hepatic impairment, and with CYP2D6 poor metabolizers.
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Renal elimination of metabolites accounts for ~60% of the dose; <5% excreted unchanged. Fecal excretion ~40% via bile.
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Category A/B
Category C
Antihistamine
Antihistamine